The ASPIRE-AECC project. a clinical trial aimed at developing new therapeutic approaches to improve survival in hepatocellular carcinoma, the most common type of liver cancer. Funded by the Spanish Association Against Cancer and its Scientific Foundation, the study is being conducted within a multicenter consortium that brings together leading oncology teams. Within this framework, IDIVAL participates thanks to the collaboration of Carlos López, whose contribution is essential to the progress of the project.
In the field of scientific dissemination, López, from the Medical Oncology Department at Marqués de Valdecilla University Hospital, presented the ASPIRE-AECC project during the post‑ESMO regional meeting held in La Rioja. His presentation made it possible to outline the objectives of the trial and highlight its relevance in driving new therapeutic strategies against hepatocellular carcinoma. His participation in this event strengthened the project’s visibility within the oncology community, fostering knowledge exchange and stimulating interest in this line of research.
The ASPIRE-AECC project represents a firm commitment to oncology research aimed at improving the prognosis of people with liver cancer through the development of innovative therapies grounded in scientific evidence.
